A Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo)

NCT00152490 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

604

Enrollment

INDUSTRY

Sponsor class

Conditions

Crohn's Disease

Interventions

DRUG: Certolizumab Pegol (CDP870)

Sponsor

UCB Pharma